pH-sensitive lipid materials, their preparation methods and applications; targeted cationic liposomes, their preparation methods and applications
By combining pH-sensitive lipid materials with silengiptide (CGT), targeted cationic liposomes have solved the problem of the lack of targeting of chemotherapy drugs, achieving precise release of chemotherapy drugs at the tumor site and enhancing the effect of chemotherapy.
Patent Information
- Application Number
- CN202310288656.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-20
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-03-20
AI Technical Summary
Current chemotherapy drugs lack targeting, resulting in toxic side effects on both tumor cells and normal cells, making precise targeted drug delivery impossible.
By combining pH-sensitive lipid materials with the targeted peptide silengitide (CGT), chemotherapy drugs are released through the cleavage of hydrazone bonds in the tumor microenvironment, achieving precise targeted drug delivery.
It increases the concentration of chemotherapy drugs at the tumor site, reduces toxic side effects on normal tissues, improves the tumor immune microenvironment, and enhances the efficacy of chemotherapy.
Smart Images

Figure CN116355055B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biotechnology, specifically to a pH-sensitive lipid material, its preparation method and uses, and a targeted cationic liposome, its preparation method and uses. Background Technology
[0002] Chemotherapy drugs are medications used to treat tumors. They kill tumor cells. These drugs act on different stages of tumor cell growth and reproduction, inhibiting or killing the cells. Chemotherapy is currently one of the main methods for treating tumors.
[0003] However, chemotherapy drugs lack targeting ability; they can inhibit and kill tumor cells, but they can also inhibit and kill normal cells, resulting in serious toxic side effects on the body. Summary of the Invention
[0004] This invention addresses the technical problem of the inability of existing chemotherapy drugs to be precisely targeted for delivery by providing a pH-sensitive lipid material, its preparation method and uses, and a targeted cationic liposome, its preparation method and uses.
[0005] The first aspect of this invention provides a pH-sensitive lipid material, the structural formula of which is:
[0006]
[0007] A second aspect of the present invention provides a method for preparing pH-sensitive lipid materials, comprising the following steps:
[0008] Distearate phosphatidylethanolamine-polyethylene glycol-carboxyl group reacts with oxaloyl dihydrazide under predetermined conditions, followed by dialyzing and lyophilization to obtain intermediate A;
[0009] p-Formylbenzoic acid was dissolved in a stable solvent and reacted with an equimolar amount of intermediate A, followed by dialyzing and lyophilization to obtain intermediate B.
[0010] The intermediate B was dissolved in a stable solvent and reacted with silengiptide under the predetermined conditions, followed by dialysis and lyophilization to obtain a pH-sensitive lipid material.
[0011] The third aspect of the present invention provides the application of the pH-sensitive lipid material provided in the first aspect of the present invention or the method for preparing pH-sensitive lipid material provided in the second aspect of the present invention in the preparation of liposomes.
[0012] A fourth aspect of this invention provides a targeted cationic liposome, comprising phospholipids, auxiliary lipids, a pH-sensitive lipid material, and a chemotherapeutic agent, wherein the pH-sensitive lipid material has the following structural formula:
[0013]
[0014] The fifth aspect of this invention provides a method for preparing the targeted cationic liposomes provided in the fourth aspect of this invention, comprising the following steps:
[0015] The phospholipid, the auxiliary lipid, and the pH-sensitive lipid material were prepared into a lipid membrane.
[0016] The lipid membrane was hydrated using a buffer solution containing the chemotherapeutic drug to obtain a hydrated lipid membrane;
[0017] The hydrated lipid membrane is sonicated with a probe to obtain the targeted cationic liposomes.
[0018] The sixth aspect of this invention provides the use of a targeted cationic liposome prepared by the method for preparing targeted cationic lipids as described in the fourth aspect or the method for preparing targeted cationic liposomes as described in the fifth aspect in the preparation of a drug for treating tumors.
[0019] Compared to existing technologies, the pH-sensitive lipid material of this invention includes silengilide, a targeting peptide that can bind to the lipid material via hydrazone bonds. Under the active targeting of silengilide, it is directed to the tumor microenvironment and deep parts of solid tumors. Tumor cells continuously and dynamically shape the tumor microenvironment for tumor growth through direct or indirect contact with various components in the microenvironment. Studies have shown that this tumor microenvironment is acidic. Under low pH conditions, the hydrazone bonds binding silengilide to the lipid material will break. On the one hand, silengilide can be released to act on tumor cells and tumor stromal cells. On the other hand, the pH-sensitive lipid material can be used to prepare liposomes as carriers for chemotherapeutic drugs. The silengilide targets tumor cells and tumor stromal cells, and then the hydrazone bonds break in the tumor microenvironment, releasing silengilide and chemotherapeutic drugs simultaneously, achieving precise targeted drug delivery, increasing drug concentration at local sites, reducing toxic side effects in normal tissues and organs, and improving the tumor immune microenvironment.
[0020] The targeted cationic liposomes provided by this invention have good targeting and biocompatibility, enabling co-encapsulation of multiple chemotherapeutic drugs, avoiding the first-pass effect in the liver, improving pharmacokinetic properties, and prolonging circulation time in vivo. Attached Figure Description
[0021] Figure 1 This is a schematic flowchart of a method for synthesizing pH-sensitive lipid materials provided in the third aspect of an embodiment of the present invention;
[0022] Figure 2 for Figure 1 The diagram shows the synthetic route for pH-sensitive lipid materials.
[0023] Figure 3This is a schematic flowchart of a method for preparing targeted cationic liposomes provided in the fourth aspect of the present invention;
[0024] Figure 4A For paraformylbenzoic acid 1 H-NMR spectrum, Figure 4B For CGT 1 H-NMR spectrum, Figure 4C For DSPE-PEG 2000 -COOH 1 H-NMR spectrum, Figure 4D For intermediate B 1 H-NMR spectrum, Figure 4E The pH-sensitive lipid material provided in Embodiment A1 of the present invention 1 H-NMR spectrum;
[0025] Figure 5A The FT-IR spectrum of paraformylbenzoic acid. Figure 5B The FT-IR spectrum of CGT, Figure 5C For DSPE-PEG 2000 FT-IR spectrum of -COOH Figure 5D The FT-IR spectrum of intermediate B. Figure 5E The FT-IR spectrum of the pH-sensitive lipid material provided in Embodiment A1 of the present invention;
[0026] Figure 6A For DSPE-PEG 2000 DSC spectrum of -COOH Figure 6B The DSC spectrum of CGT. Figure 6C The DSC spectrum of the pH-sensitive lipid material provided in Embodiment A1 of the present invention;
[0027] Figure 7A This is the particle size distribution diagram of CLs-GEM / CGT liposomes provided in Embodiment A2 of the present invention. Figure 7B This is a Zeta potential distribution map of CLs-GEM / CGT liposomes provided in Embodiment A2 of the present invention. Figure 7C This is a transmission electron microscope image of CLs-GEM / CGT liposomes provided in Embodiment A2 of the present invention;
[0028] Figure 8A This is a particle size distribution diagram of CLs-GEM liposomes provided in Comparative Example A2 of this invention. Figure 8B This is a Zeta potential distribution diagram of CLs-GEM liposomes provided in Comparative Example A2 of this invention. Figure 8C This is a transmission electron microscope image of CLs-GEM liposomes provided in Comparative Example A2 of this invention;
[0029] Figure 9AThe image shows the flow cytometry uptake of human pancreatic cancer cells PANC-1 in each experimental group 2 hours after uptake. Figure 9B Flow cytometry uptake plots of Huh-7 liver cancer cells for each experimental group at 2 hours of uptake.
[0030] Figure 10 Confocal uptake maps of human pancreatic cancer cells PANC-1 for each experimental group;
[0031] Figure 11 Figure showing the cytotoxicity of unloaded cationic liposome carriers (CLs) to PANC-1 cells;
[0032] Figure 12 The diagram shows the inhibitory effect of each experimental group on the proliferation of PANC-1 cells. Detailed Implementation
[0033] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only a part of the embodiments of the present invention, and not all of them. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0034] The first aspect of this invention provides a pH-sensitive lipid material, which comprises distearate-phosphatidylethanolamine-polyethylene glycol-carboxyl (DSPE-PEG) 2000 -COOH), oxaloyl dihydrazide, p-formylbenzoic acid, and cilengitide (L-arginylglycyl-L-aspartic-D-phenylalanyl-N-methyl-L-valine, CGT), DSPE-PEG 2000 -COOH is chemically bonded to oxaloyl dihydrazide, oxaloyl dihydrazide is chemically bonded to p-formylbenzoic acid, and p-formylbenzoic acid is chemically bonded to CGT. Specifically, the structural formula of the pH-sensitive lipid material is:
[0035]
[0036] It should be noted that CGT is a selective inhibitor of αvβ3 integrin and a targeting peptide. It binds to lipid materials via hydrazone bonds and is actively targeted to the tumor microenvironment and deep parts of solid tumors. Tumor cells continuously and dynamically shape the tumor microenvironment for tumor growth through direct or indirect contact with various components in the microenvironment. Studies have shown that this tumor microenvironment is acidic. Under low pH conditions, the hydrazone bonds binding CGT to the lipid materials will break. On the one hand, this can release CGT, which acts on tumor cells and tumor stromal cells. On the other hand, pH-sensitive lipid materials can be used to prepare liposomes as carriers for tumor drugs. CGT targets tumor cells and tumor stromal cells, and then the hydrazone bonds break in the tumor microenvironment, releasing CGT and tumor drugs simultaneously. This achieves precise targeted drug delivery, increases drug concentration at local sites, reduces toxic side effects in normal tissues and organs, and improves the tumor immune microenvironment.
[0037] A second aspect of this invention provides a method for preparing a pH-sensitive lipid material, which is used to prepare the pH-sensitive lipid material of the first aspect of this invention. Please refer to... Figure 1 and Figure 2 ,in, Figure 1 This is a schematic flowchart of a method for preparing pH-sensitive lipid materials according to a second aspect of the present invention. Figure 2 for Figure 1 The diagram shown illustrates the synthetic route for pH-sensitive lipid materials. This method includes the following steps:
[0038] Step 101: Distearate phosphatidylethanolamine-polyethylene glycol-carboxyl group reacts with oxaloyl dihydrazine under predetermined conditions, followed by dialyzing and lyophilization to obtain intermediate A;
[0039] In this embodiment, the predetermined conditions include a room temperature stirring reaction environment, that is, the reaction is carried out by continuous stirring at room temperature.
[0040] Furthermore, the predetermined conditions also include catalytic reaction conditions, with the catalyst being 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS), i.e., DSPE-PEG. 2000 -COOH reacts with oxaloyl dihydrazine under EDC and NHS catalysis to generate intermediate A containing a hydrazine bond. Specifically, the reaction includes the following steps:
[0041] DSPE-PEG 2000 - COOH, EDC and NHS are added to pure water in a predetermined ratio and stirred for the first predetermined time;
[0042] Oxaloyl dihydrazide was dissolved in pure water by ultrasonication, and then DSPE-PEG was added. 2000The reaction mixture of COOH, EDC and NHS was stirred at room temperature, dialyzed and lyophilized to obtain intermediate A.
[0043] The predetermined ratio can be 1:3:3 (molar ratio), the first predetermined time can be 2 hours, and the preferred number of dialysis cycles is three. The mixture of oxaloyl dihydrazine and DSPE-PEG... 2000 The catalytic reaction time of -COOH can be set according to actual needs.
[0044] In some embodiments, the structural formula of intermediate A is:
[0045]
[0046] In some embodiments, oxaloyl dihydrazide and DSPE-PEG 2000 The preferred molar ratio of -COOH is 2:1.
[0047] Step 102: Dissolve p-formylbenzoic acid in a stable solvent, react with an equimolar amount of intermediate A, dialyze and freeze dry to obtain intermediate B;
[0048] In this embodiment, the stabilizing solvent can be dimethyl sulfoxide (DMSO). p-Formylbenzoic acid is dissolved in DMSO and reacted with intermediate A to generate intermediate B containing a hydrazone bond. Specifically, the process includes the following steps:
[0049] p-Formylbenzoic acid was added to a dimethyl sulfoxide solution, dissolved by sonication, and an equimolar amount of intermediate A was added. The mixture was stirred at room temperature, dialyzed, and lyophilized to obtain intermediate B.
[0050] The amount of p-formylbenzoic acid can be 0.05 mmol, and the reaction time between p-formylbenzoic acid and intermediate A can be set as needed.
[0051] In some embodiments, the structural formula of intermediate B is:
[0052]
[0053] Step 103: The intermediate B is dissolved in a stable solvent and reacted with silengiptide under the predetermined conditions, followed by lyophilization via dialyze to obtain a pH-sensitive lipid material.
[0054] In this embodiment, the stabilizing solvent can be dimethyl sulfoxide (DMSO). Intermediate B is dissolved in the stabilizing solvent and undergoes a condensation reaction with CGT to generate the pH-sensitive lipid material DSPE-PEG. 2000 -CGT specifically includes the following steps:
[0055] Add intermediate B into DMSO, and continue to add the predetermined amounts of EDC and NHS, stirring at room temperature for a second predetermined time;
[0056] CGT was added to intermediate B, intermediate B, EDC and NHS reaction solution, stirred at room temperature, and dialyzed with pure water to obtain pH-sensitive lipid material.
[0057] The amount of intermediate B can be 0.032 mmol, the amount of CGT can be 0.038 mmol, and the molar ratio of p-formylbenzoic acid to CGT is preferably 5:4; the second predetermined time can be 2 hours, the number of pure water dialysis cycles is preferably three, and the reaction time for adding intermediate B to CGT can be set according to actual needs.
[0058] The third aspect of the present invention provides the application of a pH-sensitive lipid material prepared by the method for preparing a pH-sensitive lipid material provided in the first aspect of the present invention or the method for preparing a pH-sensitive lipid material provided in the second aspect of the present invention in the preparation of liposomes.
[0059] The fourth aspect of the present invention provides a targeted cationic liposome, which includes phospholipids, auxiliary lipids, pH-sensitive lipid materials and chemotherapeutic drugs. The pH-sensitive lipid material is the pH-sensitive lipid material provided in the first aspect of the present invention or the pH-sensitive lipid material prepared by the method for preparing pH-sensitive lipid materials provided in the second aspect of the present invention.
[0060] In some embodiments, the phospholipid may be soybean phospholipid (SPC).
[0061] In some embodiments, the auxiliary lipids include cholesterol (Chol), DC cholesterol (DC-Chol), and distearate phosphatidylethanolamine-polyethylene glycol (DSPE-PEG). 2000 ).
[0062] In a further embodiment, phospholipids, Chol, DC-Chol, and DSPE-PEG are used. 2000 The molar ratio of pH-sensitive lipid materials is 7:6:1:0.08:0.06.
[0063] In some embodiments, the chemotherapy drug includes gemcitabine (GEM), and the molar ratio of phospholipid to gemcitabine is 2:1 to 10:1.
[0064] In some embodiments, the chemotherapy drug is gemcitabine, paclitaxel, or docetaxel, or other chemotherapy drugs. Those skilled in the art can select different chemotherapy drugs for different tumors according to actual needs.
[0065] In a further embodiment, the final concentration of GEM can be 0.5-10 mg / ml, preferably 1-5 mg / ml, and more preferably 1 mg / ml.
[0066] In a further embodiment, the molar ratio of phospholipid to GEM can be from 2:1 to 10:1, preferably 5:1.
[0067] In some embodiments, chemotherapy drugs include a variety of drugs.
[0068] In some embodiments, the particle size of the targeted cationic liposomes is 100-300 nm, preferably 100-200 nm.
[0069] In some embodiments, the potential of the targeted cationic liposomes is 20-50 mV, preferably 20-40 mV.
[0070] It should be noted that targeted cationic liposomes possess excellent targeting and biocompatibility, enabling the co-encapsulation of multiple chemotherapeutic drugs while avoiding the first-pass effect in the liver, improving pharmacokinetic properties, and prolonging circulation time in vivo. Here, we will use GEM as an example to illustrate its mechanism of action. GEM is encapsulated in liposomes, and under the active targeting of CGT, the targeted cationic liposomes are guided to the tumor microenvironment and deep within solid tumors. The tumor microenvironment is acidic; under the low pH conditions of the tumor microenvironment, hydrazone bonds break, releasing CGT and GEM, which act on tumor cells and tumor stromal cells, increasing local drug concentration, reducing toxic side effects on normal tissues and organs, improving the tumor immune microenvironment, and simultaneously killing tumor cells. Furthermore, GEM and CGT have a synergistic effect in tumor treatment.
[0071] A fifth aspect of this invention provides a method for preparing targeted cationic liposomes, which is used to prepare the targeted cationic liposomes of the fourth aspect of this invention. Please refer to... Figure 3 The above is a flowchart illustrating a method for preparing targeted cationic liposomes according to a fourth aspect of the present invention. The method includes the following steps:
[0072] Step 201: Phospholipids, auxiliary lipids, and pH-sensitive lipid materials are used to prepare a lipid membrane;
[0073] The pH-sensitive lipid material in this embodiment is the pH-sensitive lipid material provided in the first aspect of this invention, or the pH-sensitive lipid material prepared by the method for synthesizing pH-sensitive lipid materials provided in the second aspect of this invention. Specifically, it includes the following steps:
[0074] Phospholipids, auxiliary phospholipids, and pH-sensitive lipid materials were dissolved in organic solvents and vacuum dried using a rotary evaporator to form lipid films.
[0075] The organic solvent may be chloroform or a mixture of chloroform and methanol.
[0076] Step 202: The lipid membrane is hydrated using a buffer solution containing chemotherapy drugs to obtain a hydrated lipid membrane;
[0077] In this embodiment, the buffer solution can be a 5% glucose solution or a PBS buffer solution, and the hydration time is preferably 5-30 min to ensure sufficient hydration.
[0078] Step 203: The probe is used to sonicate the hydrated lipid membrane to obtain targeted cationic liposomes.
[0079] In this embodiment, a 30W-80W probe ultrasound can be used, and the ultrasound time can be 1-20 minutes, preferably 3-10 minutes.
[0080] Understandably, by using different chemotherapy drugs, specifically preparing CGT-modified targeted cationic liposomes loaded with different chemotherapy drugs, targeted cationic liposomes can be prepared to treat the cancer corresponding to the chemotherapy drug. For example, if the chemotherapy drug is GEM, then CGT-modified targeted cationic liposomes containing GEM can be used to treat pancreatic cancer.
[0081] The sixth aspect of this invention provides the application of a targeted cationic liposome in the preparation of a drug for treating tumors. The targeted cationic liposome is the targeted cationic liposome provided in the fourth aspect of this invention or the targeted cationic liposome prepared by the method for preparing targeted cationic liposomes in the fifth aspect of this invention.
[0082] The seventh aspect of this invention provides the use of a CGT-modified targeted cationic liposome containing GEM in the preparation of a medicament for treating pancreatic cancer.
[0083] The foregoing describes the pH-sensitive lipid materials and their preparation methods, as well as the targeted cationic liposomes and their preparation methods provided by the present invention. To ensure that the details and operations of the above embodiments of the present invention are clearly understood by those skilled in the art, and to demonstrate the significant improvements in the performance of the pH-sensitive lipid materials and their preparation methods, and the targeted cationic liposomes and their preparation methods, the following examples illustrate the above technical solutions.
[0084] Table 1. Reagents and Materials
[0085]
[0086]
[0087] Table 2 Instrument List
[0088] Fully automated enzyme-linked immunosorbent assay (ELISA) Bio-Rad, USA CO2 cell incubator SANYO Corporation of Japan Inverted microscope Olympus Japan -80℃ ultra-low temperature freezer SANYO Corporation of Japan Clean bench Suzhou Sujie Chemical Equipment Co., Ltd. liquid nitrogen tank MVE Company, USA Milipore Water Purifier Milipore, Germany SGC-8 type water bath Ningbo Xinzhi Scientific Instruments Research Institute BS110S Series Electronic Balance Beijing Sartorius Balance Co., Ltd. Nzno ZS-90 Zetasizer Analyzer Malvern Instruments, UK Tensor27 Fourier Transform Infrared Spectrometer KBr tablets, Bruker GmbH, Germany Avance 500 nuclear magnetic resonance spectrometer Bruker, Germany Differential scanning calorimeter Mettler-Toledo SB25-12D Ultrasonic Cleaner Ningbo Xinzhi Biotechnology Co., Ltd. Thermostatic oscillator Changzhou Aohua Instrument Co., Ltd. S3400N Scanning Electron Microscope Hitachi Japan FV-1000 confocal microscope Olympus Japan CanII flow cytometer BD Company, USA Rotary evaporator German company BUCHI Autoclave Shanghai Boxun Co., Ltd. Ultrasonic cell disruptor Ningbo Xinzhi Biotechnology Co., Ltd.
[0089] Example A1. Preparation of pH-sensitive lipid materials
[0090] DSPE-PEG with a molecular weight of 2850 2000 -COOH, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), and N-hydroxysuccinimide (NHS) were accurately weighed in a molar ratio of 1:3:3 and added to pure water. The mixture was stirred for 2 hours. Oxaloyl dihydrazide was added to pure water and dissolved by sonication. DSPE-PEG 2000 The molar ratio of -COOH to oxaloyl dihydrazine is 1:2. The mixture is added to the above reaction solution, stirred at room temperature overnight, dialyzed three times, and lyophilized to obtain a white solid, i.e., intermediate A.
[0091] 0.05 mmol of p-formylbenzoic acid was added to dimethyl sulfoxide (DMSO) and dissolved by sonication. An equimolar amount of intermediate A was added to the solution, and the mixture was stirred overnight at room temperature. The reaction solution was dialyzed and lyophilized to obtain a white solid, namely intermediate B.
[0092] 0.032 mmol of intermediate B was added to DMSO, and a certain amount of EDC and NHS were added to the reaction solution. The mixture was stirred at room temperature for 2 hours. 0.038 mmol of CGT was added to the above reaction solution, and the mixture was stirred at room temperature overnight. The reaction solution was dialyzed three times with pure water to obtain the pH-sensitive lipid material DSPE-PEG. 2000 -CGT.
[0093] The synthesized DSPE-PEG was processed in the following manner. 2000 -CGT is used for characterization.
[0094] 1. Using nuclear magnetic resonance hydrogen spectroscopy (NMR) 1 H-NMR) of the prepared DSPE-PEG 2000 Characterization was performed using -CGT, and the chemical shifts of different hydrogen atoms in the spectrum were analyzed to determine its structure. Tetramethylsilane (TMS) was used as an internal reference, and chloroform was used as the solvent. Please refer to the detection results. Figure 4A , 4B 4C, 4D and 4E, among which, Figure 4A For paraformylbenzoic acid 1 H-NMR spectrum, Figure 4B For CGT 1 H-NMR spectrum, Figure 4C For DSPE-PEG 2000 -COOH 1 H-NMR spectrum, Figure 4D For intermediate B 1 H-NMR spectrum, Figure 4E The pH-sensitive lipid material provided in Embodiment A1 of the present invention 1 H-NMR spectrum. As can be seen from the figure, DSPE-PEG...2000 The characteristic peak of -CGT in the 1H NMR spectrum at 7.85 ppm is the H on the benzene ring in the structure of p-formylbenzoic acid, where the benzoyl group reacts with the hydrazine group to form a hydrazone bond. δ7.16 ppm (d) and δ7.12 ppm (d) are the H on the benzene ring in CGT. δ3.66-3.43 ppm (m, polyethylene glycol) is the peak of DSPE-PEG. 2000 The presence of the hydrogen atom in polyethylene glycol within the -COOH structure indicates that the prepared DSPE-PEG... 2000 -CGT combines the properties of CGT and DSPE-PEG. 2000 The structural characteristics of -COOH.
[0095] 2. FT-IR analysis of the prepared DSPE-PEG 2000 Characterization was performed using -CGT, and the peak values of functional groups in the compound were detected to analyze its infrared characteristic peaks. Please refer to the detection results. Figure 5A , 5B 5C, 5D and 5E, among which, Figure 5A The FT-IR spectrum of paraformylbenzoic acid. Figure 5B The FT-IR spectrum of CGT, Figure 5C For DSPE-PEG 2000 FT-IR spectrum of -COOH Figure 5D The FT-IR spectrum of intermediate B. Figure 5E This is the FT-IR spectrum of the pH-sensitive lipid material provided in Example A1 of this invention. As can be seen from the figure, the characteristic absorption peak of intermediate B is similar to that of DSPE-PEG. 2000 The infrared spectra of -COOH are similar, but differ in that a strong peak appears at 1648, which corresponds to the C=N stretching vibration region of the hydrazone bond; the absorption peak at 1557 corresponds to the C=C stretching vibration region of the benzene ring, indicating the introduction of hydrazone bonds and a benzene ring into the structure. DSPE-PEG 2000 The characteristic absorption peaks of -CGT are similar to those of intermediate B in the infrared spectrum, except that the 1736 absorption peak in the spectrum of intermediate B is replaced by DSPE-PEG. 2000 The 1714 absorption peak in the -CGT spectrum indicates substitution. The 1736 absorption peak corresponds to the C=O stretching vibration region of the carboxylic acid, suggesting that DSPE-PEG... 2000 -COOH successfully binds to CGT via hydrazone bonds.
[0096] 3. Differential scanning calorimetry (DSC) was used to analyze the prepared DSPE-PEG. 2000 -CGT was used for characterization, and DSPE-PEG was analyzed. 2000 -Heat flux change after CGT synthesis. Detection conditions: initial temperature -20℃, final temperature 300℃, heating rate 10℃ / min, nitrogen atmosphere. Detection results are shown in 6A, 6B, and 6C. Figure 6AFor DSPE-PEG 2000 DSC spectrum of -COOH Figure 6B The DSC spectrum of CGT. Figure 6C This is the DSC spectrum of the pH-sensitive lipid material provided in Example A1 of the present invention. As can be seen from the figure, the main characteristic peaks of CGT are at 222℃ and 296℃; DSPE-PEG... 2000 The main characteristic peaks of -COOH are at 51℃ and 54℃; DSPE-PEG 2000 The characteristic peaks of -CGT at 48℃ and 52℃ indicate that the product DSPE-PEG was obtained during preparation. 2000 -CGT is different from CGT and DSPE-PEG. 2000 A new compound with -COOH.
[0097] Example A2. Preparation of CGT-modified cationic liposomes containing GEM (CLs-GEM / CGT)
[0098] SPC, cholesterol (Chol), DC-Chol, and DSPE-PEG 2000 and the DSPE-PEG prepared in Example A1 2000 CGT was dissolved in chloroform at a molar ratio of 7:6:1:0.08:0.06, and a lipid film was formed by rotary evaporation. A certain amount of 5% glucose solution containing GEM was added, and the mixture was hydrated for 10 min to make the final concentration of GEM 1 mg / ml. Then, the mixture was sonicated at 50 W for 5 min to obtain uniformly sized cationic liposomes CLs-GEM / CGT containing GEM modified with CGT.
[0099] The final CLs-GEM / CGT liposomes were milky white in appearance, becoming transparent after film deposition. The CLs-GEM / CGT liposomes had a relatively uniform particle size of approximately 191 nm. Figure 7A As shown, the potential of CLs-GEM / CGT liposomes is around 30.9 mV, as... Figure 7B As shown, CLs-GEM / CGT liposomes, observed under transmission electron microscopy, are spherical with uniform particle size and good dispersibility. Figure 7C As shown.
[0100] Comparative Example A2. Preparation of cationic liposomes containing GEM (CLs-GEM)
[0101] SPC, Chol, DC-Chol and DSPE-PEG 2000GEM was dissolved in chloroform at a molar ratio of 7:6:1:0.24 and rotary evaporated to form a lipid film. A certain amount of 5% glucose solution containing GEM was added and hydrated for 10 min to make the final concentration of GEM 1 mg / ml. Then, the mixture was sonicated at 50 W for 5 min to obtain cationic liposomes CLs-GEM with uniform particle size.
[0102] The final CLs-GEM liposomes were milky white in appearance, becoming transparent after thin-film deposition. The particle size of the CLs-GEM liposomes was relatively uniform, approximately 184 nm. Figure 8A The potential of CLs-GEM liposomes is around 23.6 mV, such as Figure 8B As shown, CLs-GEM liposomes, observed under transmission electron microscopy, appear as spherical particles with uniform size and good dispersibility. Figure 8C As shown.
[0103] Preparation of A3.CGT-modified cationic liposomes (CLs-CGT) in comparative example
[0104] The preparation method of CLs-CGT in Comparative Example A3 is basically the same as that in Example A2, except that GEM is not added during preparation, which will not be described again here.
[0105] The preparation of Example A2 and Comparative Example A2 has been described above. The following two experiments will be used to evaluate the in vitro uptake effect of CLs-GEM liposomes and CLs-GEM / CGD liposomes.
[0106] Experiment 1
[0107] Human pancreatic cancer cells (PANC-1) and liver cancer cells (Huh-7) were seeded in 12-well plates and cultured overnight at 37°C in a 5% CO2 incubator before cell uptake experiments. Following the preparation method of Comparative Example A2, fluorescent coumarin C6 was used instead of GEM to prepare cationic liposomes containing CLs-C6. Following the preparation method of Example A2, fluorescent coumarin C6 was used instead of GEM to prepare cationic liposomes containing CLs-C6 / CGT. A certain amount of fluorescent coumarin C6 was weighed and dissolved in an appropriate amount of DMSO to obtain free coumarin C6. Free C6 and the two types of liposomes were diluted with culture medium and added to the corresponding wells, so that the final concentration of CGT in each well was 5 μg / mL, and the corresponding final concentration of coumarin C6 was 2.5 μg / mL. After incubation at 37°C for 2 h, the same volume of culture medium was used as a blank control, and Free C6 was used as a negative control. Positive cells in each group were quantified using flow cytometry. For the detection results, please refer to [link to relevant documentation]. Figure 9A and 9B ,in, Figure 9AThe image shows the flow cytometry uptake of human pancreatic cancer cells PANC-1 in each experimental group 2 hours after uptake. Figure 9B The figure shows the flow cytometry uptake of Huh-7 liver cancer cells by each experimental group after 2 hours of uptake. As can be seen from the figure, compared to the negative control group Free C6, both PANC-1 cells and Huh-7 cells showed significant uptake of CLs-C6 liposomes and CLs-C6 / CGT liposomes. However, the cells showed a stronger uptake of CLs-C6 / CGT liposomes than CLs-C6 liposomes. Furthermore, compared to Huh-7 cells with low CGT expression, CLs-C6 / CGT liposomes showed a stronger uptake of PANC-1 cells with high CGT expression, indicating that CGT further enhanced the penetration effect.
[0108] Experiment 2
[0109] PANC-1 cells were seeded in 12-well plates and cultured overnight at 37°C in a 5% CO2 incubator before cell uptake experiments. Following the preparation method of Comparative Example A2, fluorescent coumarin C6 was used instead of GEM to prepare cationic liposomes containing CLs-C6. Following the preparation method of Example A2, fluorescent coumarin C6 was used instead of GEM to prepare cationic liposomes containing CLs-C6 / CGT. A certain amount of fluorescent coumarin C6 was weighed and dissolved in an appropriate amount of DMSO to obtain Free C6. The Free C6 and the two types of liposomes were diluted and added to the corresponding wells, so that the final concentration of CGT in each well was 5 μg / mL, and the corresponding final concentration of coumarin C6 was 2.5 μg / mL. After incubation at 37°C for 2 h, Free C6 was used as a negative control, and qualitative uptake was performed using a live cell workstation. For the detection results, please refer to [link to relevant documentation]. Figure 10 The figure shows the confocal uptake of human pancreatic cancer cells PANC-1 in various experimental groups. As can be seen from the figure, compared to the negative control group Free C6, PANC-1 cells showed some uptake of both CLs-C6 liposomes and CLs-C6 / CGT liposomes. However, PANC-1 cells exhibited stronger uptake of CLs-C6 / CGT liposomes than CLs-C6 liposomes, further indicating that CGT enhanced the permeability.
[0110] Furthermore, the present invention employs two experiments to illustrate the inhibitory effect of Example A2 and Comparative Example A2 on the proliferation of human pancreatic cancer cells.
[0111] Experiment 3. Cytotoxicity of unloaded cationic liposome carriers (CLs)
[0112] Select a 96-well plate. Add 100 μl of blank vector per well according to different DC-Chol concentrations in the liposomes, with 5 replicates per group. After 24 hours, add 10 μl of MTT to each well and incubate at 37°C for 4 hours. Discard the supernatant, add 100 μl of DMSO to each well, and incubate at 37°C for 10 minutes. Measure the absorbance at 490 nm using a microplate reader. See [link to results] for details. Figure 11 The graph shows the cytotoxicity of unloaded cationic liposome carriers (CLs) to PANC-1 cells. As can be seen from the graph, when calculated according to C... DC-Chol When the blank vector was administered at a concentration of 60 μg / ml, nearly 40% of the cells died. Further increases in vector concentration led to an even higher cell death rate. When administered according to C... DC-Chol When administered at a carrier concentration ≤30 μg / ml, no significant cell death was observed, and the ionosome carrier showed no significant toxicity. Therefore, subsequent experiments used a carrier concentration C0. DC-Chol ≤30μg / ml.
[0113] Experiment 4. Inhibitory effect of CGT peptide-modified cationic liposomes (CLs-GEM / CGD) on the proliferation of human pancreatic cancer cells.
[0114] Six experimental groups were set up. The first group was Free-GEM, containing only GEM, obtained by dissolving 1 mg of GEM in 1 ml of 5% glucose solution. The second group was Free-CGT, containing only CGT, obtained by dissolving a certain amount of CGT in an appropriate amount of DMSO. The third group was Free-GEM / CGT, containing both GEM and CGT. The fourth group was CLs-GEM liposomes prepared according to Comparative Example A2. The fifth group was CLs-CGT prepared according to Comparative Example A3. The sixth group was the CLs-GEM / CGT experimental group prepared according to Example A2. Based on the amount of GEM, the liposomes were diluted to different concentrations using culture medium, i.e., C0. GEM Concentrations were: 0.02, 0.2, 2, 20, 40, and 80 μg / ml, corresponding to C0. CGT The concentrations were: 0.01, 0.1, 1, 10, 20, and 40 μg / ml (when the GEM concentration in the liposomes was 20 μg / ml, the CGT concentration was 10 μg / ml). 100 μl was injected into each well of a 96-well plate to induce PANC-1 cell growth. After 24 h, 10 μl of methylthiazolyldiphenyl-tetrazolium bromide (MTT) was added to each well, and the plate was incubated at 37°C for 4 h. The supernatant was removed and discarded. 100 μl of DMSO was added to each well, and the plate was incubated at 37°C for 10 min with shaking. The absorbance at 490 nm was measured using a microplate reader. Please refer to the attached image for the results. Figure 12The figure shows a comparison of the inhibitory effects of different experimental groups on PANC-1 cell proliferation. As can be seen from the figure, with the increase of GEM concentration, PANC-1 cell proliferation was gradually inhibited. GEM At a concentration of 20 μg / ml, cell growth was inhibited by nearly 50%, followed by significant inhibition and even mass cell death. At 80 μg / ml, cell death was essentially achieved; therefore, 20 μg / ml is the optimal dosage concentration. Furthermore, it can be seen that compared to CLs-GEM and CLs-CGT alone, CLs-GEM / CGT more significantly inhibited cell proliferation, indicating a synergistic effect between GEM and CGT. Moreover, the inhibitory effect of CLs-GEM / CGT is superior to that of Free-GEM and CLs-GEM, suggesting that CGT modification of cationic liposomes enhances the inhibitory effect on cell proliferation. CLs-GEM / CGT liposomes can significantly inhibit the proliferation of pancreatic cancer cells, suggesting therapeutic potential for pancreatic cancer.
[0115] The above description is only a part of the embodiments of the present invention and does not limit the patent scope of the present invention. Any equivalent structural or procedural transformations made based on the content of the present invention specification and drawings, or direct or indirect applications in other related technical fields, are similarly included within the patent protection scope of the present invention.
Claims
1. A pH-sensitive lipid material, the structural formula of which is: 。 2. A method for preparing the pH-sensitive lipid material as described in claim 1, characterized in that, Includes the following steps: Distearate phosphatidylethanolamine-polyethylene glycol-carboxyl group and oxaloyl dihydrazine were reacted under predetermined conditions, dialyzed and lyophilized to obtain intermediate A. The predetermined conditions included a room temperature stirring reaction environment and catalytic reaction conditions. The catalysts were 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide. p-Formylbenzoic acid was dissolved in a stable solvent and reacted with an equimolar amount of intermediate A. The reaction was then dialyzed and lyophilized to obtain intermediate B. The stable solvent was dimethyl sulfoxide. The intermediate B is dissolved in the stable solvent and reacted with silengiptide under the predetermined conditions, followed by dialysis and lyophilization to obtain the pH-sensitive lipid material.
3. The application of the pH-sensitive lipid material according to claim 1 or the pH-sensitive lipid material prepared by the method according to claim 2 in the preparation of liposomes.
4. A targeted cationic liposome, characterized in that, It includes phospholipids, auxiliary lipids, pH-sensitive lipid materials, and chemotherapeutic drugs, wherein the structural formula of the pH-sensitive lipid material is: 。 5. The targeted cationic liposome according to claim 4, characterized in that, The chemotherapy drug is gemcitabine, and the molar ratio of the phospholipid to the gemcitabine is 2:1 to 10:
1.
6. The targeted cationic liposome according to claim 4, wherein the auxiliary lipids include cholesterol, DC cholesterol, and distearate phosphatidylethanolamine-polyethylene glycol.
7. The targeted cationic liposome according to claim 6, characterized in that, The molar ratio of the phospholipid, the cholesterol, the DC cholesterol, the distearate phosphatidylethanolamine-polyethylene glycol, and the pH-sensitive lipid material is 7:6:1:0.08:0.
06.
8. A method for preparing the targeted cationic liposomes as described in claim 4, characterized in that, Includes the following steps: The phospholipid, the auxiliary lipid, and the pH-sensitive lipid material were prepared into a lipid membrane. The lipid membrane was hydrated using a buffer solution containing the chemotherapeutic drug to obtain a hydrated lipid membrane; The hydrated lipid membrane is sonicated with a probe to obtain the targeted cationic liposomes.
9. The use of a targeted cationic liposome according to any one of claims 4-7 or a targeted cationic liposome prepared by the method for preparing targeted cationic liposomes according to claim 8 in the preparation of a medicament for treating human pancreatic cancer.
